Polyplus Completes Acquisition of Xpress Biologics

Polyplus, a solution provider for manufacturing of Advanced Therapeutic Medicinal Products from research to commercial grade, has announced the completed acquisition of Xpress Biologics, a Belgian contract development and manufacturing organization (CDMO) specialized in the production of plasmid DNA and protein using microbial expression systems.  Article Summary The acquisition will strategically expand the Polyplus plasmid […]

Neogene Therapeutics to Be Acquired by AstraZeneca

Neogene Therapeutics, Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development, and manufacturing of next-generation T-cell receptor therapies (TCR-Ts), has announced it has entered into a definitive agreement to be acquired by AstraZeneca. Article Summary With a shared goal of bringing cell therapies to patients with solid tumors, Neogene’s expertise in TCR-T discovery, […]

Emmes Launches Cell and Gene Therapy Center to Support Its Client’s Clinical Trials

Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, has announced the creation of a dedicated center to enhance Emmes’ legacy and depth in cell and gene therapy research. Article Summary The new center will emphasis on supporting the clinical trials of its clients who are […]

Catalent Opens Cell Therapy Manufacturing Facilities in Belgium

Catalent has announced the completion and opening of one of the world’s largest commercial-scale cell therapy manufacturing facility at its European center of excellence for cell therapies, in Gosselies, Belgium. Article Summary The new facility is established with 60,000 square feet (5,600 square meters) of dedicated cell therapy manufacturing space housing multi-product, segregated suites designed […]

Thermo Fisher Scientific Introduces All-in-One AAV Production System

The Gibco CTS AAV-MAX Helper-Free AAV Production System, a new all-in-one solution from Thermo Fisher Scientific, has been developed to help fulfil clinical and business demands for the affordable and scalable production of adeno-associated virus (AAV)-based gene treatments. It is currently the only product of its kind to be produced following cGMP guidelines in order […]

Researchers at University Hospitals Seidman Cancer Center and a Biotech Start-Up Company Streamline Way to Manufacture CAR T-cells for Immunotherapy Treatment in 24 Hours

A simplified method for producing CAR T-cells for immunotherapy treatment in just 24 hours has been devised by researchers at University Hospitals Seidman Cancer Center and a biotech start-up business. Article Summary This ground breaking new development will expedite the delivery of CAR T therapy to those who need it most. Researchers stated that the […]

Kriya Acquires Redpin Therapeutics, Adding Neurology Pipeline to Gene Therapy Portfolio

Kriya Therapeutics, Inc., a fully integrated gene therapy company with a wide range of portfolio of innovative therapeutics, has announced the acquisition of Redpin Therapeutics, Inc., a private biotechnology company developing regulatable gene therapies for intractable diseases of the nervous system. Article Summary The acquisition serves as the foundation for Kriya’s neurology therapeutic area portfolio, […]

BioLineRx Received US FDA Approval for NDA for APHEXDA® (motixafortidenew ) in Stem Cell Mobilisation

BioLineRx Ltd, a pre-commercial-stage biopharmaceutical company has announced that the U.S. FDA has accepted for review and filed the Company’s New Drug Application (NDA) for APHEXDA® (motixafortide) in stem cell mobilization for autologous transplantation in multiple myeloma patients. Article Summary Autologous stem cell transplantation (ASCT) is part of the standard treatment paradigm for several blood […]

Thermo Fisher Scientific Unveils Closed and Automated Cell Isolation and Bead Removal System to Help Evolve Cell Therapy Manufacturing

Excerpt Thermo Fisher Scientific Inc. has unveiled the Gibco™ CTS™ DynaCellect™ Magnetic Separation System (DynaCellect) to help cell therapy developers easily move from process and clinical development to commercial manufacturing.  Article Summary This next-generation cell isolation, cell activation, cell depletion and Dynabeads™ magnetic beads removal instrument provides a scalable, flexible, automated and closed system to […]

Scribe Therapeutics Announces Research Collaboration with Sanofi to Accelerate Breakthrough CRISPR-based Cell Therapies for Cancer

Excerpt Scribe Therapeutics Inc., a molecular engineering company pioneering a CRISPR by Design™ platform for genetic medicine, has announced a strategic collaboration with Sanofi to grant the non-exclusive license to Scribe’s CRISPR genome editing technologies that can enable genetic modification of novel natural killer (NK) cell therapies for cancer. Article Summary The agreement grants Sanofi […]

Kite’s Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in 2nd Line B-cell Lymphoma

Excerpt Kite, a Gilead Company has announced that the European Commission (EC) has granted approval for the use of Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) who relapse within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. Article Summary […]

Gene Therapy Trial Starts for Parkinson’s Disease by Researchers in Japan

Researchers of Jichi Medical University Hospital in Japan have started a trial of a treatment for Parkinson’s disease by injecting genes into a patient. This is reportedly the first clinical trial of this treatment method in the country. Article Summary The team has injected the genes directly into a male patient’s brain, with the aim […]